SXI Life Sciences
7.772,36
PKT
-3,32
PKT
-0,04
%
Werbung
Leider sind zu diesem Wert keine aktuellen Kursdaten verfügbar, die Stammdaten finden Sie im unteren Seitenbereich.
Analysen zu SXI Life Sciences-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 30.03.22 | Roche Buy | Merrill Lynch & Co., Inc. | |
| 30.03.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 30.03.22 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 30.03.22 | Roche Outperform | Bernstein Research | |
| 29.03.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 22.03.22 | Novartis Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 14.03.22 | Novartis Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 11.03.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 03.03.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 21.02.22 | Roche Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 17.02.22 | Novartis Neutral | UBS AG | |
| 16.02.22 | Roche Buy | Deutsche Bank AG | |
| 11.02.22 | Roche Neutral | UBS AG | |
| 11.02.22 | Roche Buy | Jefferies & Company Inc. | |
| 09.02.22 | Novartis Neutral | UBS AG | |
| 09.02.22 | Novartis Equal-weight | Morgan Stanley | |
| 09.02.22 | Roche Buy | Deutsche Bank AG | |
| 07.02.22 | Roche Buy | Deutsche Bank AG | |
| 07.02.22 | Roche Overweight | Barclays Capital | |
| 04.02.22 | Roche Overweight | Barclays Capital | |
| 04.02.22 | Roche Neutral | UBS AG | |
| 03.02.22 | Novartis Neutral | UBS AG | |
| 03.02.22 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.02.22 | Novartis Sell | Deutsche Bank AG | |
| 03.02.22 | Novartis Neutral | Credit Suisse Group | |
| 03.02.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 03.02.22 | Roche Buy | Jefferies & Company Inc. | |
| 02.02.22 | Novartis Market-Perform | Bernstein Research | |
| 02.02.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 02.02.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 02.02.22 | Novartis Underweight | Barclays Capital | |
| 02.02.22 | Novartis Buy | Jefferies & Company Inc. | |
| 01.02.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 31.01.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 31.01.22 | Novartis Underweight | Barclays Capital | |
| 31.01.22 | Roche Overweight | Barclays Capital | |
| 26.01.22 | Roche Buy | Deutsche Bank AG | |
| 26.01.22 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 26.01.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 25.01.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. |